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conduction abnormalities and increasing myelination on MRI 
scans. Pts transplanted later in the course of the disease have had 
less dramatic but measurable improvements, particularly in lan- 
guage and cognitive skills. We hypothesized that UCB-derived 
cells migrated to brain and differentiated into non-hematopoietic 
cells in these pts but could not study this filrther with non-inva- 
site techniques. Unfortunately, one baby with advanced Krabbe 
disease, transplanted with a UCB donor of the opposite sex at 8 
months of age, died 1 yr post transplant. Her brain was studied to 
determine whether donor derived cells were present at the time of 
her death. Brain tissue was fixed in formalin, sectioned and stained 
with histochemical stains for glial and neuronal tissues and coun- 
terstained with FISH for the XY chromosomes to differentiate 
donor and host cells. YVe found extensive distribution of host cells 
in blood vessels, peri-ventricular tissues, white matter of the cere- 
bral cortex, cerebellmn, choroid plexis and forebrain parenchyma. 
Differentiation of donor ceils to microglia and choriod plexus 
cells was present, but differentiation i to cells of neuroectodermal 
origin (e.g neurons, astrocytes, or l igodendrocytes) was not 
found. These results demonstrate hat donor-derived UCB cells 
can extensively distribute in brain tissues after UCB transplanta- 
tion. Transdifferentiation across germ cell layers was not demon- 
strated. 
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EMBRYONIC STEM CELLS SURVIVE AND PROLIFERATE AFTER 
INTRA-PERITONEAL IN UTERO TRANSPLANTATION AND PRODUCE 
TERATOCARCINOMAS 
Nedelcu, E.1; Sriwzstava, A. I; Vartei, ~L 2; Assatoztria~.r, G. 1; C[at~der, 
Ed 1. Bone 3/larrow Tva*zsplaJzt, UMversity of CA, San Diego, La 
rid~a, G4; 2. Umversity of CA, San Diego, La Jolla, Gq. 
Embryonic stem cells (ESC) support murine fetal development 
if injected in blastocysts and can engraft in conditioned newborns. 
However, little is known about their behavior after the in utero 
transplantation. The aim of this research is to establish a model 
for study of the in vivo differentiation of ESCs after the in utero 
transplantation. We hypothesize that the in ntero transplanted 
ESC integrate into the fetus and, based on their pluripotency, may 
represent a therapeutic alternative for prenatally diagnosed is- 
eases. ESC genetically engineered to express yellow fluorescent 
protein (YFP-ESC) were transplanted intra-peritoneally in ntero 
at E 14-15. The presence of YFP signal was analyzed in various tis- 
sue of the viable offsprings at different ages (4-8 weeks) and was 
quantified by digitalized fluorescence microscopy on analysis of 
tissue supernatants. The YFP-ES-derived cells were found only in 
the liver without any evidence of YFP signal in other organs. 
Extensive peritoneal teratocarcinomas with snpradiaphragmatic 
involvement was generated after the ESC in in utero transplanta- 
tion in allogeneic mice. Also, clinical and histopathological pic- 
tures suggestive of graft-versus -host disease were present in two 
out of five haploidentical mice. Studies that address the issue of 
ESC differentiation i to hepatic ceils within this model are in 
process and will be presented. The promise and the potential risks 
of the ESC transplantation have to be carefully considered. 
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BRAIN FROM BLOOD IN HUMANS 
Cogle, C.Rd; Zander, D.S.2; Dzchnis, TS; Ste&dler, D.A.Z; WiJzgard, 
ff.Rd; Scott, E.~Vd 1. U~liversity ofFlorida, Gai~esville, FL; 2. Uni- 
versity of Texas, Ho,sto,, TX. 
Adult hematopoietic stem cells (HSC) have the capacity to 
self-renew and differentiate into all hematopoietic lineages. 
Recent  studies in humans have found that bone marrow 
derived stem cells can function as regenerative progenitors for 
the liver, kidney, heart, musculoskeletal tissue, and gastroin- 
testinal tract. In the brain, animal studies have found that 
murine HSC can differentiate into neurons of the adult mouse. 
Following these reports, we investigated whether human HSC 
contribute to adult human neurogenesis. Autopsy brain speci- 
mens from female recipients of therapeutic HSC transplanta- 
tion from male donors where analyzed for cells containing Y
chromosome. In these cases, hippocampai ceils containing Y 
chromosome were found. Most Y-positive cells were non-neu- 
ronal, with transgender neurons (beta-3-tubulin positive) com- 
prising only 1% of total neurons. In addition, these Y-chromo- 
some neurons were not a product of fusion, as evidenced by 
presence of only one X chromosome. Our findings demonstrate 
that postnatal human neuropoiesis i present and that human 
hematopoietic cells have the capability to generate neurons, 
albeit at a very low level. The biologic implications uggest 
that the HSC or a hematopoiet ic  progeni tor  esponds to 
instructive neurotrophic ues, crosses the blood-brain-barrier, 
diffuses into central nervous system tissues and activates previ- 
ously dormant neuron-specific genetic programming. Together 
these observations challenge the restricted notion of unidirec- 
tional ontogenic maturation and uncover a mount ing HSC 
plasticity repertoire. Our findings also suggest hat human 
HSC may serve as a therapeutic source for regenerative neu- 
ropoiesis. 
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AUTOLOGOUS STEM CELL COLLECTION IN POLYCYTHEMIA VERA 
Lrola, L.; Gorsky, M.; SiMtsylla, K; ScigliaT~o, E.; Frztc,~tma,, S. 
Hematology, 3do~mt Shzai Medical Center, New York, NIT. 
Allogeneic Tx can eradicate MF. We reported resolution of MF 
after ablative syngeneic Tx in a patient with spent phase PV (B J 
Haematol f i7:246). Hence GvL is not required to eliminate MF. 
Ablation with ASCT could represent a major advance for spent 
phase PV. In PV, the optimal t iming and the influence of 
organomegely, myelosnppression a d MF on autologous collec- 
tion are uknown. Between 08/94 and 01/02, 16 pts with PV 
underwent stem cell collection. Mobil ization was G-CSF 10 
mcg/kg x 5d. Min imum target was 2.5 X 106 CD34+/kg. All 
myelosnppression but anagrelide was stopped aminimum of 2 w~ 
before collection. M:F ratio was 7/9. Median ages at Dx and col- 
lection were 47 and 57. Organomegaly was present in 10 pts 
(63%) and moderate or extensive MF in 4 pts (25%). Seven pts 
were receiving myelosuppression. Three pts had clonal cytogenet- 
ic abnormalities. For the whole cohort median TNC and CD34+ 
counts were 8.3 X 108/kg and 4.98 X 10~/kg. No organomegaly 
predicted for higher TNC and lower CD34+ contents but differ- 
ences were NS (p=0.16 and 0.1). MF adversely affected TNC 
(p=0.05) but not CD34+ (p=0.8). Time from Dx and myelosuppre- 
sion had no influence on TNC and CD34+ . One pt had CD34+ 
below target (2.2 X 106/kg). See table for details. Autologous col- 
lection of peripheral blood stem cells is feasible in PV pts several 
years after DX. Organomegaly and MF are not contraindications 
for collection. Myelosuppresion up to 2 weeks prior to mobiliza- 
tion appears safe in terms of cell contents. Studies are now 
required to determine the safety and efficacy of ablation and 
ASCT to reestablish effective hematoposiesis in spent PV. 
TNC e8/kg CD34+ e6&g 
N Y N Y 
Organomegaly 12,2 6.6 ! 3,06 8.30 
TfromDx>10y 0.7 8.7 ! 2.9 i i .9 f 
MF 10.3 3.8 i 6.09 3.25 
Myelosuppression 8.4 9.1 i 3.7 9.8 
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PREFERENTIAL EXPANSION OF CORD BLOOD EARLY PROGENITORS 
ENABLED BY LINEAR POLYAMINE COPPER CHELATORS 
Peled, T.t; Nagler, A.2; Treves, A.J. 1 1. Gamida-Cell, Jer~lsalem, 
Israel; 2. Sheba Medical Center, T l Hashomer, Israel. 
We demonstrated that the polyamine copper chelator, tetraeth- 
ylenepentamine (TEPA), extended the long term cord blood 
CD34+ cultures (Peled tal, Brit. J. Haematol. 116:655 2002 ).To 
study the effect of TEPA on long-term expansion, we adopted a
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two phase culture system that enables the distinction between the 
expansion of early and late progenitors. In the first phase (3 
weeks), the cultures were supplemented with both TEPA and 
cytokines (FLt3, SCF, TPO, IL-6). In the second phase (addition- 
al 5-7 weeks) the cultures were supplemented with cytokines 
alone, in the absence of TEPA. Late progenitors (CD34+ and 
CFUc) as well as early progenitor cells (CD34+CD38-, 
CD34+Lin-(CD38, 33, 14, 15, 61, 41, 3, 4, 19), CD34+38-HLA- 
DR-) were measured at the termination of the treatment phase 
(week 3) as well as at different intervals during the long-term assay 
phase. After the first phase (3w), TEPA cultures contained signifi- 
cantly higher percentages of early progenitors (21% CD34+38- 
+/- 3.8; 7.0% CD34+Lin- +/-1.9, 1.5%+/-0.5 CD34+38-HLA- 
DR, n=9-) as compared to the control, only cytokine treated cul- 
tures (2.6% CD34+38- +/ 1, 0.9% CD34+Lin- +/-0.3, 0% 
CD34+38-HLA-DR- n=9 ). At the same time, no differences were 
noticed in the late progenitors (TNC, CFUc and CD34+ cells) 
between control and TEPA cultures. Fold expansion of CD34+ 
ceils in both control and treated cultures was in the range of 10-40 
(N=6) folds. After the second phase (additional 5-7w) in the 
TEPA pre-treated cultures, CD34+ cells expanded by 370-1320 
folds (N=6) whereas no CD34+ cells could be recovered in control 
cultures. CFUc expansion i  TEPA pre-treated cultures was by 20 
to 30 folds (n=6) higher than in the control cultures. These results 
indicated that the chelator enabled preferential proliferation of 
early progenitors during the first three weeks. At this stage, no 
positive or negative ffect on the expansion of late progenitors and 
TNC was obsmwed. These early progenitors continued to prolif- 
erate and differentiate during the TEPA free phase and supported 
the extensive xpansion of late progenitors during the long term 
cultures.The chelator based method of three weeks ex vivo expan- 
sion, which resulted in a cell graft enriched in early progenitors 
increased by 10 told the engraftment in SCID mice. We plane to 
test the safety and efficacy of such a graft in clinical cord blood 
transplantation. 
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THE PRESENCE CXCR4 ON CD34+ CELLS WAS ASSOCIATED WITH 
THE EFFECTIVENESS OF G-CSF PBPC MOBILIZATION 
Lange, A.; Dlnbek, D.; Skrzypele, D.; Pacuszko, T. B3/IT Unit, Lov:er 
Sile,@m C2,ntre for Celhdar Tiwlspla77tation/Institute of l~nm'm~olo~y 
and Experimental Therapy, WROCL4 ~V, Polmzd. 
The presence of CXCR4 on CD34+ cells plays a role in 
hematopoietic progenitors rafficking" and reflects the stage of 
these cells dif ferentiat ion. The most primitive cells are 
CXCR4 strongly positive than they loose this epitope and 
gain it again while become DR positive. Therefore, we inves- 
tigated the proportions of CXCR4+ and DR+ cells among 
CD34+ cells in ninety G-CSF mobilized leukapheresis prod- 
ucts (PBPC) obtained from fifty eight volunteer, healthy 
donors and in thirty one bone marrow harvests (BM) for allo- 
geneic grafting'. Marrow transplant materials differed from 
PBPC with respect to the proport ions of CD34+ cells 
(0.91%+-0.07 vs 0.64%+-0.04, p=0.001) which were, however, 
to the similar proport ion DR negative (14.15%+-1.81 vs 
13.89%+-1.44). Looking at the co-expression of CXCR4 and 
DR on CD34+ cells, it was found that PBPC CD34+ cells 
were more frequently CXCR4-DR+ as compared to marrow 
(48.42%+-2.45 vs 39, 34%+-4.38, p=0.05). Marrow CD34+ 
cells were more frequently CXCR4+ than those in PBPC 
(62.47%+-4.09 vs 50.91%+-2.47, p=0.02). PBPC preparations 
were richer in CD34+ cells if the latter cells were in higher 
proportions CXCR4 negative (r=0.45, p=0.00001), in variance, 
marrows harvested for transplantation contained more CD34+ 
cells if they were CXCR4+ (r=0.34, p=0.06) It may be con- 
cluded that the presence of CXCR4 on CD34+ ceils influ- 
enced the yield of transplant material in hematopoietic pro- 
genitors. The coexopression of CXCR4 on CD34+ cells made 
the marrow harvest richer in hematopoietic progenitors but 
the content of CD34+ cells in G-CSF mobilized PBPC signif- 
icantly depended on the presence of CD34+ cells lacking 
CXCR4. 
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SIBLING DONOR CORD BLOOD (SDCB) BANKING AND TRANSPLAN- 
TATION FOR CHILDREN WITH SICKLE CELL ANEMIA AND THA- 
LASSEMIA: CHILDRENS HOSPITAL OAKLAND SIBLING DONOR CORD 
BLOOD PROGRAM, 
Lubin, B.H.: Reed, ~'V.; f'Valte'rs, M. ChildreJ~'s ttospirnl Oakland 
Research bzstitnte, Oakland, CA. 
Sickle cell anemia nd thalassemia are two genetic diseases with 
a worldwide incidence. Vffhile current reatment protocols for 
these patients have improved their lives, hematopoctic stem cell 
(HSC) transplantation is the only current reatment that offers a 
promise of cure. The donor for a HSC transplant is most often an 
HLA matched sibling. Recent evidence suggests that umbilical 
cord blood (CB), obtained from a sibling, may provide an impor- 
tant source of HSCs for these transplants. \Ve have developed a
National SDCB Banking program to provide a resource to evalu- 
ate CB transplantation. Our bank has fascilitated the collection of 
over 200 CB samples for families who already had a child with 
sickle cell anemia or thalassemia.. The volume of CB (average 100 
ml) collected and the nucleated cell counts were sufficient o pro- 
vide at least 2.5x107 cells/kg recipient weight in 85% of the cases. 
Taken together with recent results reported by NETCORD, a 
total of 44 children with henroglobinopathies (33 thalassemia, 11 
sickle cell anemia) have been transplanted with HLA matched 
SDCB. 85% appear to have been cured. The remaining children 
failed to engraft and had a return of disease. Minimal GVHD was 
noted. None of the children died as a result of the transplant. 
~eVhile acommon transplant protocol was not followed, our results 
suggest that modification of the conditioning regimen and provid- 
ing a critical nucleated cell dose will enhance ngraftment and 
improve outcome. We conclude that SCDB banking should be 
available to all families who currently have a child with sickle cell 
anemia or thalassemia. A prospective study to determine the opti- 
mal regime for SDCB transplantation is currently underway. 
229 
OPTICAL IMAGING OF EARLY POST-TRANSPLANT DESTINY OF BONE 
MARROW PROGENITOR CELLS IN MICE 
Doubrovin, 3/[.M. I; 3/layer-R)Mezdc, p.2; B~ldak ~tlpogalz, T. i; Vm~ cle~7 
Brink, M.1; BaJze~jee, D.~; GelovaJTi Tjltvnjev, ft.1 1. Nez~rology, 
3/ISKCC, New ~rk, NY," 2. The Cancer bzstitute New fferse~, Robert 
~'Vood ffohlTsolz ]VIedical School, New Brmzs'wick, Nff. 
Use of non-invasive isualization techniques to follow up the 
destiny of transplanted hematopoietic stem cells provide a reliable 
tool for investigation of the processes of transplant engraftment 
and reconstitution of hematopoiesis. Bone marrow, harvested 
from C57BL/6-Ly.1 donor mice, was negatively sorted for differ- 
entiation determined c lls. The obtained enriched population of 
bone marrow precursor cells (BMPC) was stably transfected with 
ecotropic retrovirus carrying TK-dmDHFR and GFP-Luc 
chimeric genes. Transfected cells were positively selected on 
FACSVantage using GFP-expression signal. 10A4 BMPC were 
reinfused as a rescue of lethally irradiated C57BL/6-Ly.2 recipient 
mice. D-lueiferin was administered either in vivo, immediately 
post-transplant, or ex vivo, directly to the BMPC, in two animal 
groups: Bioluminescent imaging (BLI) was started in 5 minutes 
after the BMPC. For the follow up studies, d-luciferin was admin- 
istered I.V. to all animal groups. Control group included irradiat- 
ed animals without BMPC support. BLI revealed a weak, but dis- 
tinctive signal accumulation in the projection of lungs and 
mediastinum with animals in supine position. Dilution of BMPC 
local concentration resulted in disappearance of any detectible sig- 
nal between hours 36 and 60. Further obsmwation demonstrated 
BMPC localization to the final hematopoietic sites. Higher signal 
was registered in the animals inoculated with the ex vivo d- 
lueiferin preineubated BMPC. No specific signal was identified in 
the control group. ~/Veak sources of photons associated with the 
projection of open skin/mucosa areas corresponded to the subin- 
flared thermal photon background. Early migration of a small 
nmnber of stem cells can be efficiently monitored using highly 
sensitive bioluminescence approach. Systemic BMPC dose lower 
limits for sensitivity of BLI registration were identified. Triple 
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